criticism has been rightly drawn over the prohibitive cost of these drugs for low-income and middle-income countries (lmics). although these drugs will be offered to lmics at a discounted price, they are still too expensive for many countries to scale up treatment.
to advance treatment and improve qual酒精肝降糖ity of care for patients, the lancet has established a commission on liver disease in the uk, which is due to report its findings later this year. further efforts to implement effective treatment of hcv, and to combat liver cirrhosis, in lmics are badly needed.
management of liver cirrhosis
肝硬化的发病率和死亡成都酒精肝率不断增加,每年导致超过100万例患者死亡
丙肝引起的肝硬化要比乙肝引起的肝硬化多4月9日,在欧洲肝病研究学会(easl)年会上,世界卫生组织(who)首次发布了丙肝指南该指南为各国丙肝的筛查及治疗提供了路线图,还特别对医疗资源有限地区的丙肝治疗提供指导意见
fda批准每片1000美元的抗丙肝新药sofosbuvir
liver cirrhosis is an increasing cause of morbidity and mortality, responsible for more than 1 million deaths annually. in today'slancet, a seminar by emmanu诊断酒精肝el tsochatzis and colleagues describes liver cirrhosis as the fourteenth most common cause of death worldwide. in developed countries, the leading causes of liver cirrhosis are hepatitis c virus (hcv), alcohol misuse, and non-alcoholic liver disease; whereas hepatitis b virus (hbv) is the most common ca中度酒精肝的治疗方法use in sub-saharan africa and most parts of asia. hepatocellular carcinoma is the leading cause of death in patients with liver cirrhosis, and management of hepatocellular carcinoma is complicated by liver cirrhosis in more than 80% of patients.
为了更好的治疗和护理肝硬化患者,柳叶刀杂志在英国建立了一个肝病委员会,旨在今年晚些时候汇报关于肝病研究的新发现在中低哪里治疗酒精肝好收入国家落实丙肝的有效治疗措施、与肝硬化作斗争是迫切需要我们努力的方向
资讯详情:[easl2014]世卫组织发布首份丙型肝炎治疗指南(附指南全文)
(本网站所有内容,凡注明来源为“医脉通”,版权均归医脉通所有,欢迎转载,但请务必注明出处,否则将追究法律责任本网注明来源为其他媒体的内容为转载,转载仅作观点分享,版权归原作者所有,如有侵犯版权,请及时联系我们)
according to who estimates, the prevalence of hcv infection varies substantially by region. for example, east and south asia have 轻度酒精肝怎么治疗high population hcv prevalence rates (of 3?7% and 3?4%, respectively), which accounts for more than 100 million patients infected with hcv. several new drugs to treat hcv infection are in development. recently, the us food and drug administration approved simeprevir and sofosbuvir, and the european medicines a非酒精性脂肪肝gency approved sofosbuvir.
资讯详情:fda批准simeprevir联合治疗基因1型丙肝
然而,新药的价格对于中低收入国家的患者来说过高,因此,这些新药也饱受争议尽管这些新药将在中低收入国家打折销售,但对于大多数国家来说,药价依然很高,难以大范围推广
根据who预测,丙肝的患病率因不同地域而变化比如,东亚和南亚国家的丙肝患病率均较高(分别为3.7%和3.4%),hcv感染总人数超过1亿几种治疗丙肝的新药正在研发中最近,美国fda已经批准simeprevir和sofosbuvir上市,欧洲药品管理局也批准了sofosbuvir上市在近期的柳叶刀杂志上,emmanuel tsochatzis和他的治酒精肝哪里好同事将肝硬化描述为世界上第十四大常见的死亡原因在发达国家,肝硬化的主要病因包括丙型肝炎病毒(hcv),酒精滥用和非酒精性肝病;而乙型肝炎病毒(hbv)是撒哈拉以南的非洲及大部分亚洲地区肝硬化的主要病因肝癌是导致肝硬化患者死亡的主要病因,超过80%的肝癌患者合并肝硬化
阅读英文原文
more cases of liver cirrhosis are caused by hcv than hbv. on april 9, the first who guidelines for hcv were released to coincide with the european association for the st酒精肝 治疗udy of the liver (easl) congress in london, uk. these guidelines give countries a roadmap for screening and treatment of hepatitis c, with specific guidance on how to start treatment in resource-limited settings.
北京治白癜风哪个医院好治疗白癜风的方法